Advertisement
Advertisement

SPRY

SPRY logo

ARS Pharmaceuticals, Inc. Common Stock

10.03
USD
Sponsored
+0.36
+3.67%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

9.98

-0.04
-0.45%

SPRY Earnings Reports

Positive Surprise Ratio

SPRY beat 10 of 20 last estimates.

50%

Next Report

Date of Next Report
Mar 18, 2026
Estimate for Q4 25 (Revenue/ EPS)
$26.10M
/
-$0.44
Implied change from Q3 25 (Revenue/ EPS)
-19.71%
/
-15.38%
Implied change from Q4 24 (Revenue/ EPS)
-69.86%
/
-189.80%

ARS Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On Nov 10, 2025, SPRY reported earnings of -0.52 USD per share (EPS) for Q3 25, missing the estimate of -0.48 USD, resulting in a -8.02% surprise. Revenue reached 32.50 million, compared to an expected 29.53 million, with a 10.06% difference. The market reacted with a +8.36% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 analysts forecast an EPS of -0.44 USD, with revenue projected to reach 26.10 million USD, implying an decrease of -15.38% EPS, and decrease of -19.71% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, ARS Pharmaceuticals, Inc. Common Stock reported EPS of -$0.52, missing estimates by -8.02%, and revenue of $32.50M, 10.06% above expectations.
The stock price moved up 8.36%, changed from $8.20 before the earnings release to $8.88 the day after.
The next earning report is scheduled for Mar 18, 2026.
Based on 8 analysts, ARS Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.44 and revenue of $26.10M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement